Brentuximab vedotin is used to treat several types of blood cancers, especially those that express the CD30 protein. It is indicated for:

Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma, in combination with chemotherapy.
Pediatric patients (2 years and older) with previously untreated high-risk classical Hodgkin lymphoma, in combination with chemotherapy.
Adult patients with classical Hodgkin lymphoma at high risk of relapse or progression after autologous stem cell transplant (as consolidation therapy).
Adult patients with classical Hodgkin lymphoma after failure of stem cell transplant or after failure of at least two prior chemotherapy regimens.
Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas, in combination with chemotherapy.
Adult patients with relapsed sALCL, primary cutaneous ALCL, or CD30-expressing mycosis fungoides who have received prior systemic therapy.
Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), in combination with lenalidomide and rituximab, after two or more lines of systemic therapy who are not eligible for stem cell transplant or CAR T-cell therapy.

Your healthcare provider will determine if brentuximab vedotin is appropriate for you based on your specific diagnosis and treatment history.